Treatment data in 1318 Brazilian SpA patients.
| Treatment | White, n = 857 | African Brazilian, n = 413 | Other, n = 48 | p |
|---|---|---|---|---|
| Mean delay between first symptoms and diagnosis, yrs | 6.47 ± 7.90 | 6.68 ± 7.51 | 7.61 ± 7.26 | 0.793 |
| Physical exercise, mean hours/week | 1.72 ± 2.90 | 1.67 ± 3.46 | 2.14 ± 3.18 | 0.607 |
| NSAID use*, n (%) | 574 (67) | 286 (69.2) | 41 (85.4) | 0.025† |
| NSAID efficacy**, n (%) | 562 (65.6) | 289 (70) | 44 (91.7) | < 0.0001† |
| Corticosteroids, n (%) | 346 (40.4) | 119 (28.8) | 25 (52.1) | < 0.0001†† |
| Sulfasalazine, n (%) | 372 (43.4) | 188 (45.5) | 31 (64.6) | 0.015† |
| Methotrexate, n (%) | 457 (53.3) | 202 (48.9) | 33 (68.8) | 0.024† |
| Infliximab, n (%) | 155 (18.1) | 54 (13.1) | 7 (14.6) | 0.073 |
| Etanercept, n (%) | 27 (3.2) | 13 (3.1) | 2 (4.2) | 0.925 |
| Adalimumab, n (%) | 25 (2.9) | 59 (1.2) | 0 | 0.09 |
↵* NSAID use: only for those taking the medications in regular daily doses.
↵** NSAID efficacy: considered when there was pain relief 48 hours after starting use, or worsening of the pain after 48 hours of drug withdrawal.
↵† Difference significant with “others”.
↵†† Difference significant between white and African Brazilian patients. NSAID: nonsteroidal antiinflammatory drugs.